KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts).
Giulio Metro
No relevant relationships to disclose
Simona Duranti
No relevant relationships to disclose
Rita Chiari
No relevant relationships to disclose
Chiara Bennati
No relevant relationships to disclose
Carmen Molica
No relevant relationships to disclose
Maria Francesca CurrÃ
No relevant relationships to disclose
Chiara Scafati
No relevant relationships to disclose
Annamaria Siggillino
No relevant relationships to disclose
Antonella Flacco
No relevant relationships to disclose
Luca Marcomigni
No relevant relationships to disclose
Vienna Ludovini
No relevant relationships to disclose
Vincenzo Minotti
No relevant relationships to disclose
Lucio Crinò
No relevant relationships to disclose